Richard Bethlehem is a postdoctoral fellow and research associate at the Autism Research Centre and Brain Mapping Unit at the University of Cambridge in the United Kingdom. He studies integrated neuroimaging and transcriptomics to gain better understanding of the biological underpinnings of typical and atypical neurodevelopment.
Richard Bethlehem
Research associate
University of Cambridge
From this contributor
Q&A with Richard Bethlehem: What goes into a Brainhack
Brainhack conferences offer talks and hands-on tutorials, and unite small groups of interdisciplinary researchers to work on open-source neuroscience projects.
Q&A with Richard Bethlehem: What goes into a Brainhack
By
Niko McCarty
9 July 2021 | 7 min read
How normative modeling can reframe autism’s heterogeneity
Normative modeling could capture variability among autistic people and allow for individualized assessments.
How normative modeling can reframe autism’s heterogeneity
By
Richard Bethlehem, Andre F. Marquand
25 February 2020 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read